Market Cap | 9.07M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -15.97M | Forward P/E | -0.18 | EPS next Y | 54.10% | 50D Avg Chg | 1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -15.00% |
Dividend | N/A | Price/Book | 1.39 | EPS next 5Y | - | 52W High Chg | -75.00% |
Recommedations | 2.00 | Quick Ratio | 0.22 | Shares Outstanding | 32.15M | 52W Low Chg | 257.00% |
Insider Own | 1.85% | ROA | -224.00% | Shares Float | 31.04M | Beta | 1.05 |
Inst Own | 0.45% | ROE | - | Shares Shorted/Prior | 364.58K/107.92K | Price | 2.18 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 475,130 | Target Price | 0.50 |
Oper. Margin | - | Earnings Date | Nov 13 | Volume | 51,264 | Change | 1.87% |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Gumulka Jerzy | Director Director | Feb 01 | Buy | 0.30 | 33,333 | 10,000 | 43,006 | 02/06/24 |
Evans Carl Anthony | Director Director | Feb 01 | Buy | 0.30 | 33,333 | 10,000 | 33,458 | 02/06/24 |
Downs Christopher | Chief Financial Offi.. Chief Financial Officer | Feb 01 | Buy | 0.30 | 66,666 | 20,000 | 103,438 | 02/06/24 |
Climaco John M | Chief Executive Offi.. Chief Executive Officer | Feb 01 | Buy | 0.30 | 166,666 | 50,000 | 215,676 | 02/06/24 |
Downs Christopher | Chief Financial Offi.. Chief Financial Officer | Aug 22 | Buy | 1.2658 | 27,000 | 34,177 | 36,772 | 08/23/23 |
Climaco John M | Chief Executive Offi.. Chief Executive Officer | Aug 16 | Buy | 1.798 | 2,750 | 4,944 | 49,010 | 08/16/23 |
Priebe Waldemar | 10% Owner 10% Owner | Dec 06 | Sell | 1.46 | 94,298 | 137,675 | 156,807 | 08/01/23 |
Downs Christopher | Chief Financial Offi.. Chief Financial Officer | Apr 17 | Buy | 3.20 | 3,100 | 9,920 | 9,251 | 04/18/23 |
Gumulka Jerzy | Director Director | Apr 10 | Buy | 0.74 | 7,173 | 5,308 | 7,173 | 04/17/23 |